Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment

Triple negative breast cancers are an aggressive subtype of breast cancer, characterized by the lack of estrogen receptor, progesterone receptor and Her2 expression. Triple negative breast cancers are non-responsive to conventional anti-hormonal and Her2 targeted therapies, making it necessary to id...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Wei Bin, Yao, Min, Brummer, Gage, Acevedo, Diana, Alhakamy, Nabil, Berkland, Cory, Cheng, Nikki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226513/
https://www.ncbi.nlm.nih.gov/pubmed/27283985
http://dx.doi.org/10.18632/oncotarget.9885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226513/
https://www.ncbi.nlm.nih.gov/pubmed/27283985
http://dx.doi.org/10.18632/oncotarget.9885

Ejemplares similares